CMYC expression in infiltrating gliomas: Associations with IDH1 mutations, clinicopathologic features and outcome

Yazmin Odia, Brent A. Orr, W. Robert Bell, Charles G Eberhart, Fausto J Rodriguez

Research output: Contribution to journalArticle

Abstract

Gliomas are among the most frequent adult primary brain tumors. Mutations in IDH1, a metabolic enzyme, strongly correlate with secondary glioblastomas and increased survival. cMYC is an oncogene also implicated in aberrant metabolism, but its prognostic impact remains unclear. Recent genotyping studies also showed SNP variants near the cMYC gene locus, associate with an increased risk for development of IDH1/2 mutant gliomas suggesting a possible interaction between cMYC and IDH1. We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity - most frequent (95 %, χ2 p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. Independent analysis of the publically available TCGA glioblastoma dataset confirmed our strong association between cMYC and mutant IDH1 expression. Both IDH1 (R132H) and cMYC protein expression were associated with improved overall survival by univariate analysis. However, cMYC co-expression associated with shortened time to malignant transformation and overall survival among IDH1 (R132H) mutants in both univariate and multivariate analyses. In summary, our findings suggest that cMYC may be associated with a unique clinicopathologic and biologic group of infiltrating gliomas and help mediate the malignant transformation of IDH1 mutant gliomas.

Original languageEnglish (US)
Pages (from-to)249-259
Number of pages11
JournalJournal of Neuro-Oncology
Volume115
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Glioma
Glioblastoma
Mutation
Astrocytoma
Oligodendroglioma
Survival
Survival Analysis
Nuclear Proteins
Oncogenes
Brain Neoplasms
Single Nucleotide Polymorphism
Analysis of Variance
Multivariate Analysis
Immunohistochemistry
Enzymes
Genes
Neoplasms
Proteins

Keywords

  • Astrocytoma
  • cMYC
  • Glioblastoma
  • Gliomas
  • IDH1
  • IDH1 (R132H)
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

CMYC expression in infiltrating gliomas : Associations with IDH1 mutations, clinicopathologic features and outcome. / Odia, Yazmin; Orr, Brent A.; Robert Bell, W.; Eberhart, Charles G; Rodriguez, Fausto J.

In: Journal of Neuro-Oncology, Vol. 115, No. 2, 2013, p. 249-259.

Research output: Contribution to journalArticle

@article{7108597466644905bb052e0f89a70ae5,
title = "CMYC expression in infiltrating gliomas: Associations with IDH1 mutations, clinicopathologic features and outcome",
abstract = "Gliomas are among the most frequent adult primary brain tumors. Mutations in IDH1, a metabolic enzyme, strongly correlate with secondary glioblastomas and increased survival. cMYC is an oncogene also implicated in aberrant metabolism, but its prognostic impact remains unclear. Recent genotyping studies also showed SNP variants near the cMYC gene locus, associate with an increased risk for development of IDH1/2 mutant gliomas suggesting a possible interaction between cMYC and IDH1. We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). Of 158 tumors with sufficient tissue, 110 (70 {\%}) showed nuclear cMYC immunopositivity - most frequent (95 {\%}, χ2 p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 {\%}) or low grade gliomas (74 {\%}). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. Independent analysis of the publically available TCGA glioblastoma dataset confirmed our strong association between cMYC and mutant IDH1 expression. Both IDH1 (R132H) and cMYC protein expression were associated with improved overall survival by univariate analysis. However, cMYC co-expression associated with shortened time to malignant transformation and overall survival among IDH1 (R132H) mutants in both univariate and multivariate analyses. In summary, our findings suggest that cMYC may be associated with a unique clinicopathologic and biologic group of infiltrating gliomas and help mediate the malignant transformation of IDH1 mutant gliomas.",
keywords = "Astrocytoma, cMYC, Glioblastoma, Gliomas, IDH1, IDH1 (R132H), Prognosis, Survival",
author = "Yazmin Odia and Orr, {Brent A.} and {Robert Bell}, W. and Eberhart, {Charles G} and Rodriguez, {Fausto J}",
year = "2013",
doi = "10.1007/s11060-013-1221-4",
language = "English (US)",
volume = "115",
pages = "249--259",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - CMYC expression in infiltrating gliomas

T2 - Associations with IDH1 mutations, clinicopathologic features and outcome

AU - Odia, Yazmin

AU - Orr, Brent A.

AU - Robert Bell, W.

AU - Eberhart, Charles G

AU - Rodriguez, Fausto J

PY - 2013

Y1 - 2013

N2 - Gliomas are among the most frequent adult primary brain tumors. Mutations in IDH1, a metabolic enzyme, strongly correlate with secondary glioblastomas and increased survival. cMYC is an oncogene also implicated in aberrant metabolism, but its prognostic impact remains unclear. Recent genotyping studies also showed SNP variants near the cMYC gene locus, associate with an increased risk for development of IDH1/2 mutant gliomas suggesting a possible interaction between cMYC and IDH1. We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity - most frequent (95 %, χ2 p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. Independent analysis of the publically available TCGA glioblastoma dataset confirmed our strong association between cMYC and mutant IDH1 expression. Both IDH1 (R132H) and cMYC protein expression were associated with improved overall survival by univariate analysis. However, cMYC co-expression associated with shortened time to malignant transformation and overall survival among IDH1 (R132H) mutants in both univariate and multivariate analyses. In summary, our findings suggest that cMYC may be associated with a unique clinicopathologic and biologic group of infiltrating gliomas and help mediate the malignant transformation of IDH1 mutant gliomas.

AB - Gliomas are among the most frequent adult primary brain tumors. Mutations in IDH1, a metabolic enzyme, strongly correlate with secondary glioblastomas and increased survival. cMYC is an oncogene also implicated in aberrant metabolism, but its prognostic impact remains unclear. Recent genotyping studies also showed SNP variants near the cMYC gene locus, associate with an increased risk for development of IDH1/2 mutant gliomas suggesting a possible interaction between cMYC and IDH1. We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111). Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity - most frequent (95 %, χ2 p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. Independent analysis of the publically available TCGA glioblastoma dataset confirmed our strong association between cMYC and mutant IDH1 expression. Both IDH1 (R132H) and cMYC protein expression were associated with improved overall survival by univariate analysis. However, cMYC co-expression associated with shortened time to malignant transformation and overall survival among IDH1 (R132H) mutants in both univariate and multivariate analyses. In summary, our findings suggest that cMYC may be associated with a unique clinicopathologic and biologic group of infiltrating gliomas and help mediate the malignant transformation of IDH1 mutant gliomas.

KW - Astrocytoma

KW - cMYC

KW - Glioblastoma

KW - Gliomas

KW - IDH1

KW - IDH1 (R132H)

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84886593066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886593066&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1221-4

DO - 10.1007/s11060-013-1221-4

M3 - Article

C2 - 23934175

AN - SCOPUS:84886593066

VL - 115

SP - 249

EP - 259

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -